STOCK TITAN

Enzon Pharma Stock Price, News & Analysis

ENZN OTC

Welcome to our dedicated page for Enzon Pharma news (Ticker: ENZN), a resource for investors and traders seeking the latest updates and insights on Enzon Pharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enzon Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enzon Pharma's position in the market.

Rhea-AI Summary
Enzon Pharmaceuticals (OTCQX: ENZN) and Viskase Companies (OTC Pink: VKSC) have announced a definitive merger agreement where Viskase will merge with Enzon's subsidiary in an all-stock transaction. The combined company will operate as Viskase Holdings and trade on OTCQX. Post-merger ownership will be distributed with Viskase stockholders owning 84.1%, Series C Preferred stockholders owning 13.84%, and current Enzon stockholders owning 2.06% of the combined company. The merger has received unanimous approval from both companies' special committees and boards. Timothy P. Feast, current CEO of Viskase, will lead the combined entity. The deal includes provisions for converting Viskase common stock and Enzon's Series C Preferred Stock into Enzon Common Stock, with specific exchange ratios. IEH and affiliates have agreed to support the merger and exchange their Series C Preferred Stock. The transaction completion is subject to stockholder approvals and regulatory clearances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Enzon Pharma (ENZN)?

The current stock price of Enzon Pharma (ENZN) is $0.081 as of June 20, 2025.

What is the market cap of Enzon Pharma (ENZN)?

The market cap of Enzon Pharma (ENZN) is approximately 7.4M.
Enzon Pharma

OTC:ENZN

ENZN Rankings

ENZN Stock Data

7.42M
30.11M
10.84%
48.58%
0.59%
Biotechnology
Healthcare
Link
United States
Cranford